- 
				
RAB32 c.213C>G (p.Ser71Arg) explains Parkinson’s disease in two UK families: description of the clinical and biochemical features
 - 
				
RAB32 variant p.Ser71Arg in the ROstock PArkinson’s Disease Study (ROPAD)
 - 
				
Racial Disparities in Hospitalization Characteristics among Native Hawaiians, Pacific Islanders and Asian American Subgroups with Restless Legs Syndrome
 - 
				
Radiofrequency Lesioning for hemidystonia: a systematic review
 - 
				
Randomized Controlled Trial of Supplementary Motor Area Transcranial Direct Current Stimulation in Tourette Syndrome
 - 
				
Rapid Cognitive Deterioration and Related Factors in Progressive Supranuclear Palsy: a One-Year Follow-up Study
 - 
				
Rapid Onset Kinematic Effects of Thalamic/Subthalamic DBS in Cervical Dystonia
 - 
				
Rapidly Progressive Pallidopyramidal Syndrome related to Parkin gene mutation
 - 
				
Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report
 - 
				
Rare Missense Variants in KCNJ10 Are Associated with Paroxysmal Kinesigenic Dyskinesia
 - 
				
Rare Variant Association Analysis in Kazakhstani Parkinson’s Disease Population: Preliminary Results from GP2 CAT-PD Study
 - 
				
Rare Variant Burden is Increased in Sporadic Late-onset Chinese Parkinson’s Disease Patients
 - 
				
Rationale and Design of the Slowing Parkinson’s Early through Exercise Dosage – United Kingdom (Slow-SPEED-UK) Trial
 - 
				
Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial
 - 
				
Raynaud’s Phenomenon and Diaphoresis During Initial Programming of Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease: A Case Report
 - 
				
RBD Unmasked: LRRK2 and the Prodromal Path to Parkinson’s Disease
 - 
				
Reaching Kinematics in Movement Disorder Patients Using an Open-Source Computer Vision Technology
 - 
				
Readiness for genetic testing among Indian movement disorder patients:A tertiary centre experience
 - 
				
Real-life experience of switching from D-penicillamine to trientine tetrahydrochloride – a nationwide registry study
 - 
				
Real-Time Removal of Stimulus Artifact for Closed-Loop Deep Brain Stimulation by Synchronized Sample-And-Hold Artifact Blanking (SSAB): Verification in Animal Model
 - 
				
Real-World Clinical and Safety Outcomes from a Prospective, Multicenter Deep Brain Stimulation Registry of Essential Tremor Patients
 - 
				
Real-World Diagnosis of Chronic Migraine in Patients With Cervical Dystonia Analyzed by Botulinum Neurotoxin Treatment Exposure: an Epidemiologic Perspective
 - 
				
Real-world Experiences of Image-guided Programming in Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s disease
 - 
				
Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents
 - 
				
Real-world Programming and Sensing from Adaptive Deep Brain Stimulation for Parkinson’s Disease in Japan
 - 
				
Real-World Retrospective Safety Analysis in Patients Treated With OnabotulinumtoxinA for Multiple Therapeutic Indications Over Repeat Treatment Periods
 - 
				
Real-world use of biomarkers for Parkinsonism: Should I do this (pSyn) or DaT?
 - 
				
Recrudescence of a Compensated Hemidystonia-hemiatrophy Syndrome After COVID-19 Infection
 - 
				
Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.
 - 
				
Reduced intestinal inflammation and increased levels of short-chain fatty acids thanks to an active lifestyle in Parkinson’s disease.
 - 
				
Reduced parietal and sensorimotor cortex recruitment during complex gait in Parkinson’s disease patients with freezing of gait
 - 
				
Reduced plasma levels of various cell signaling molecules in patients with Parkinson’s Disease
 - 
				
Reduced Thalamic Nuclei Volume May Contribute to Anxiety in Parkinson’s Disease: a 7-Tesla MRI Study
 - 
				
Refining Aesthetic Eyebrows: Botulinum Toxin Injection for Hemifacial Spasm.
 - 
				
Refining and Understanding Causal Relationships between Brain Imaging-Derived Phenotypes and Parkinson’s Disease: a Bidirectional Mendelian Randomization Study and Clinical Validation
 - 
				
REGENERATE-PD: A Phase 2, Randomized, Double-Blind, Surgery-Controlled Study of GDNF Gene Therapy (AAV2-GDNF; AB-1005) for Moderate Stage Parkinson’s Disease
 - 
				
Regional Brain Volume Differences Across PD Clinical Subtypes
 - 
				
Regional tau burden patterns and their associations with clinical severity in progressive supranuclear palsy (PSP)-Richardson’s syndrome and PSP- predominant parkinsonism: a prospective cohort study
 - 
				
Relationship Between Non-Motor Symptoms, Kinematic Features, and Quality of Life in Cervical Dystonia
 - 
				
Relationships of blood Vitamin B12 and Homocysteine with Parkinson’s Disease Progression in 3 Contemporary Clinical Trials
 - 
				
Reliability and Validity of the English Version of the Parkinson Anxiety Scale
 - 
				
Reliability of Digital Measures in Parkinson’s Disease and Their Implications for Sample Size Calculations
 - 
				
Reliability of neurophysiological and cerebral tremor features in Parkinson’s disease
 - 
				
Reliability of real-world walking activity and gait assessment in people with Parkinson’s disease – how many hours and days are needed?
 - 
				
REM sleep behavior disorder and Prodromal Parkinson’s Disease in patients with Essential Tremor
 - 
				
Remote Digital Longitudinal Assessment of Speech, Fluency and Cognitive Function in Progressive Supranuclear Palsy
 - 
				
Remote DNA Collection for Parkinson’s Research: Insights from AccessPD
 - 
				
Remote monitoring of upper limb function in Huntington’s disease using a wearable sensor
 - 
				
Remote recruitment of hyposmic participants identifies biomarkers related to neuronal alpha-synuclein disease
 - 
				
Remotely-deployed gamification intervention to increase physical activity in Parkinson’s Disease
 - 
				
Repurposing Anti-Gout Medications for the Treatment of Parkinson’s Disease
 - 
				
Research Information Disclosure In The PPMI Study: Development Of A Disclosure Process
 - 
				
Responders to a Highly Challenging Balance and Gait Intervention in People with Parkinson’s Disease
 - 
				
Response inhibition in patients with Lithium induced Tremor
 - 
				
Responsive morphometric fingerprints in deep brain stimulation for Parkinson’s disease
 - 
				
Resting state EEG source analysis identifies distinct neural signature associated with impulse control disorders in PD
 - 
				
Resting-State Network Alterations in Patients with Isolated REM Sleep Behavior Disorder and their Association with Clinical Symptoms
 - 
				
Retention Strategies in Parkinson’s Disease Clinical Studies: Findings From a Scoping Review of Recruitment and Retention Strategies
 - 
				
Reversible Hemichorea-Hemiballismus-Hemifacial Spasm in Diabetic Striatopathy
 - 
				
Reversing the irreversible: The application of Deep Brain Stimulation in The Syndrome of Irreversible Lithium Effectuated Neurotoxicity.
 - 
				
Revitalizing Lives: The Dystonia Care Rehabilitation Program
 - 
				
Risk Factors Of Parkinson’s Disease A Case-Control Study In Tunisian Patients
 - 
				
Risk Tolerance of Therapeutic Interventions in People with Parkinson’s Disease
 - 
				
Role of RNA splicing in Parkinson’s disease
 - 
				
Role of Telemedicine- Versus Outpatient-Based Initiation And Management of Atkins Diet Therapy In Postmenopausal Women With Drug-Resistant Parkinson’s Disease During The COVID-19 Pandemic
 - 
				
Role of the Alpha-synuclein Seed Amplification Assay in Parkinson’s Disease Clinical Trials: A Case Report of Multiple System Atrophy Misdiagnosed as Parkinson’s Disease
 - 
				
Role of Wearable Devices in a Physical Activity Coaching Program for People with Parkinson Disease
 - 
				
Rora deficiency aggravates dopamine neurons loss via reducing NAD+ level in Parkinson’s disease
 - 
				
Rural Tanzania’s Wide “PD Gap” Through the Decades
 
2024 International Congress
September 27-October 1, 2024. Philadelphia, PA.
